Mohammad AskarPublic working copy · medical review pending

Paediatric uveitis · 080

Paediatric uveitis: silent inflammation, grading and seven cases

Paediatric uveitis is often asymptomatic and still causes permanent visual loss. Grade the cells in a dark room, classify the anatomy and the course, then look for the systemic association that changes management.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

SUN grading needs a 1x1 mm beam and standard definitions; one quiet examination does not exclude smouldering disease. Every child needs a basic systemic screen, and the ophthalmologist must keep ownership of follow-up and treatment decisions.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Why paediatric uveitis is different

Paediatric uveitis is often asymptomatic: the eye is not red, the child does not complain, and the disease is found on screening or after vision has already dropped. That is why JIA-associated disease is described as silent. 1

The consequences accumulate: band keratopathy, posterior synechiae, cataract, glaucoma, cystoid macular oedema and amblyopia. A single normal examination does not exclude smouldering inflammation, so interval history and repeated slit-lamp examination matter. 1

Management is multidisciplinary but not leaderless. The ophthalmologist keeps responsibility for ocular follow-up, adherence and the decision to escalate, while rheumatology, nephrology and oncology manage their own domains. 1

02Classification: anatomy, type and course

Anatomical classification follows the predominant site: anterior chamber, vitreous, or retina/choroid. Panuveitis involves anterior chamber, vitreous and retina or choroid without a predominant site; it does not merely mean all uveal layers. This directs examination and systemic questions. 1

In the anterior chamber, non-granulomatous disease shows fine white keratic precipitates, while granulomatous disease shows large, greasy, yellowish mutton-fat precipitates that suggest infection or sarcoidosis. The distinction is a clue, not a diagnosis. 1

Acute disease has sudden onset and limited duration. Recurrent episodes are separated by at least 3 months of inactivity without treatment; chronic disease persists or relapses less than 3 months after stopping treatment. SUN remission requires at least 3 months of inactivity off all ocular treatment. 1 2

03Counting cells in a dark room

Dim the room to improve contrast. The original camera-obscura teaching uses a long narrow-to-medium beam at 45–60 degrees, focused between cornea and lens against the dark pupil, with fine joystick adjustments to see cells. This is a teaching technique; SUN cell grading specifically standardises a 1x1 mm slit field, not a requirement for complete darkness. 1

Use a 1x1 mm field: grade 0 is fewer than 1 cell; 0.5+ is 1–5; 1+ is 6–15; 2+ is 16–25; 3+ is 26–50; 4+ is more than 50. The original attributes fewer than 5 cells as grade 0 and acceptance of 0.5+ to UK practice; that attribution is unverified and conflicts with SUN inactivity, which requires grade 0. 1 2

Flare is protein leakage with blood-aqueous barrier disruption and is graded separately; it is not proof that the disease has become chronic. Grade cells and flare at each visit, with the same beam and the same observer where possible. This light scattering is the Tyndall phenomenon described in the original. 1 2

Counting cells in a dark room
GradeCells in a 1x1 mm fieldOriginal descriptive labels; not overall disease severity
0Fewer than 1; original 0–1 and attributed UK fewer than 5 are not SUN and remain unverified.Inactive by SUN anterior-chamber cell criterion.
0.5+1–5; not inactive by SUN, despite the original attributed UK acceptance.Minimal activity.
1+6 to 15Mild activity.
2+16 to 25Moderate activity.
3+26 to 50Severe activity.
4+More than 50Very severe activity, cells barely countable.

04Definitions that change decisions

SUN improvement is at least two steps, or reaching grade 0; worsening is at least two steps, or progression from 3+ to 4+. These thresholds matter when a chart says better without numbers. 1 2

Remission requires at least 3 months of inactive disease off all ocular treatment, rather than more than 3 months as the original says. An eye can be inactive while treated; that is distinct from remission off treatment. Record both activity and treatment status. 1 2

05Case 1: juvenile idiopathic arthritis

A 3-year-old girl had swollen ankles for six months, positive antinuclear antibodies and a negative rheumatoid factor, with no ocular symptoms. Examination showed active non-granulomatous anterior uveitis with grade 1 to 2+ cells, fine keratic precipitates, early posterior synechiae and band keratopathy. 1

JIA-associated uveitis is a major cause of noninfectious childhood uveitis, with proportions varying between populations. Its classic pattern is bilateral, chronic, nongranulomatous and silent; pain and redness may appear late after complications have developed. 1

Children with JIA need ophthalmic screening, including boys. ACR risk assessment combines JIA category, ANA positivity, age at onset and disease duration; female sex alone is not its formal high-risk definition. Choose intervals using that assessment and local protocols, rather than assuming symptoms will warn of disease. 1

06Cases 2 and 3: Blau syndrome and TINU

A 5-year-old boy had six months of recurrent fever, joint pain and a papular or nodular rash on trunk and limbs. Examination showed granulomatous anterior uveitis with mutton-fat precipitates, posterior synechiae and mildly raised intraocular pressure. 1

Arthritis, rash and recurrent uveitis together suggest childhood sarcoidosis, or Blau syndrome, which is associated with NOD2 variants. NOD2 disease is a spectrum and not every sarcoidosis is NOD2-related; infection must still be excluded in granulomatous uveitis. 1

A 13-year-old boy reported fatigue, low-grade fever, weight loss and painful red eyes. He had bilateral non-granulomatous anterior uveitis, and a urine dipstick showed proteinuria, haematuria and glycosuria with abnormal renal function. 1

TINU is an important consideration in bilateral anterior uveitis in children and adolescents. Urinalysis and renal function help investigate this association, with targeted renal assessment and nephrology input when indicated. The original recommendation to test every child is a proposed baseline approach, not proof that early detection invariably prevents irreversible renal injury. 1

07Cases 4 and 5: post-streptococcal uveitis and pars planitis

A 7-year-old girl developed sudden painful redness and photophobia about ten days after a sore throat. Examination confirmed anterior uveitis and the anti-streptolysin O titre was raised. 1

An acute uveitis one to two weeks after an upper respiratory infection, especially pharyngitis, raises the possibility of immune-mediated post-streptococcal uveitis. A raised ASO titre supports but does not confirm a single aetiology, so other causes are still considered; treatment is topical steroid and, in selected cases, antibiotics. 1

A 7-year-old girl was brought with leukocoria. Under mydriasis she had intermediate uveitis with dense vitreous cells called snowballs, exudative deposits on the peripheral retina called snowbanking and cystoid macular oedema on OCT. 1

Intermediate uveitis is a differential for floaters and blurred vision; its main complications are cystoid macular oedema and vitreous haemorrhage, and fluorescein angiography can help assess vasculitis. Pars planitis is idiopathic intermediate uveitis with snowballs or snowbanks, not a synonym for every intermediate case. 1

08Cases 6 and 7: toxocara and masquerade

An 11-year-old boy whose family kept a dog and a cat reported floaters and photophobia. He had panuveitis with chorioretinitis, vitritis, granulomatous anterior uveitis and a chorioretinal granuloma; the blood count showed marked eosinophilia. 1

Unilateral granulomatous uveitis with posterior involvement and animal contact suggests ocular toxocariasis. Eosinophilia supports the diagnosis but may be absent, so it is not mandatory; albendazole with systemic steroid cover is a specialist decision, not a universal regimen, because the aim is to limit the inflammatory response to dying parasites. 1

A 5-year-old girl in remission from an oncological disease developed a painful eye with a hypopyon that did not respond to high-dose topical steroids. A masquerade syndrome was suspected and an anterior chamber paracentesis was performed for cytology. 1

Masquerade disorders imitate primary uveitis and may themselves cause secondary inflammation; intraocular leukaemic infiltration is an important paediatric example, but the original commonest-cause claim is not verified across populations. Hypopyon is layered anterior-chamber material, not necessarily infectious pus. Leukocoria needs urgent assessment to exclude retinoblastoma. Steroid-resistant hypopyon with a cancer history needs urgent oncology and uveitis input; anterior chamber sampling is an individual specialist decision. 1

09Management: treat, taper, monitor, coordinate

Take a focused history of joints, skin, fever and infections, and assess systemic involvement. The original proposes blood count, urinalysis and blood pressure as a core screen; tailor investigations to age, presentation and suspected association rather than treating a fixed panel as diagnostic. 1

Selected noninfectious anterior uveitis may need intensive topical steroid, with hourly treatment as an original teaching example and a taper over weeks to months guided by activity. This is not a regimen for every posterior or infectious cause. Assess infection and monitor intraocular pressure, cataract and steroid response. 1

For JIA-associated noninfectious uveitis, ACR recommendations support methotrexate or selected monoclonal anti-TNF therapy according to steroid dependence, activity and sight-threatening complications, mostly with very low-certainty evidence. These recommendations do not cover every cause of childhood uveitis. High-risk JIA screening is approximately every 3 months; controlled established JIA uveitis is monitored at least every 3 months, sooner around treatment changes. Ophthalmology coordinates ocular care with the other teams. 1 3

What are the main learning points?

SUN grading needs a 1x1 mm beam and standard definitions; one quiet examination does not exclude smouldering disease. Every child needs a basic systemic screen, and the ophthalmologist must keep ownership of follow-up and treatment decisions.

When is assessment urgent?

Leukocoria needs urgent assessment to exclude retinoblastoma. Steroid-resistant hypopyon, especially with a cancer history, needs urgent specialist assessment for masquerade and other causes. Pain, falling vision or new synechiae should not wait for a routine appointment.

References and access status

  1. 1
    Immutable original export; Dr. Anas Anjari lecture export; speaker/attribution not independently verified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Standardization of Uveitis Nomenclature (SUN) working group definitions and grading

    Parent-selected access 10 November 2026: the parent reviewer read the full SUN tables 1-5 and definitions (absolute cell counts in a 1x1 mm field, improvement/worsening, remission at least 3 months off treatment). This drafting pass relied on that reported extraction and did not re-open the article.

  3. 3
    ACR/AF 2019 guideline for JIA-associated uveitis (selected table 3 and recommendations)

    10 November 2026: parent read selected table 3 and recommendations for JIA-associated uveitis, including screening and monitoring every 3 months, earlier review during treatment changes, methotrexate and selected monoclonal anti-TNF. Mostly very low-certainty evidence; dosing tables and complete guideline not appraised.

Original lecture link